Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.

Cancer research - 1 Dec 2005

da Rocha Dias Silvy, Friedlos Frank, Light Yvonne, Springer Caroline, Workman Paul, Marais Richard

Abstract excerpt

Hsp90 is a ubiquitously expressed molecular chaperone that folds, stabilizes, and functionally regulates many cellular proteins. The benzoquinone ansamysin 17-allylamino-17-demethoxygeldanamycin (17-AAG) is an anticancer drug that disrupts Hsp90 binding to its clients, causing their degradation through the ubiquitin-dependent proteasomal pathway. The protein kinase B-RAF is mutated in approximately 7% of human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzoquinones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Chlorocebus aethiops

Share to COS Cells

Share to HSP90 Heat-Shock Proteins

Share to Lactams, Macrocyclic

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 16322212
DOI: 10.1158/0008-5472.CAN-05-2632

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.PMID 16322212Read ↗

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.Semantic proximity Read ↗

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.Semantic proximity Read ↗

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.Semantic proximity Read ↗

Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.Semantic proximity Read ↗

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.Semantic proximity Read ↗

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.Semantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism.Semantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycinSemantic proximity Read ↗

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).Semantic proximity Read ↗

Geldanamycin and its derivatives as Hsp90 inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.